Complejo Hospitalario Universitario de Vigo
Centro asistencial
Publicaciones en las que colabora con José Ramón González Juanatey (158)
2024
-
Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study
Diseases, Vol. 12, Núm. 10
-
Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial
Journal of the American Heart Association, Vol. 13, Núm. 19, pp. e035460
2023
-
Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial
International Journal of Cardiology, Vol. 391
-
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593
-
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372
-
Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342
-
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study
European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360
-
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis
Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75
-
Trends in cardiovascular care in the National Health System in Spain. Data from the RECALCAR project 2011-2020
Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 519-530
2022
-
Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries
Frontiers in Cardiovascular Medicine, Vol. 9
-
Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252
-
Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study
Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 372-379
2021
-
Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke
Therapeutic Advances in Chronic Disease, Vol. 12
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433
-
Prognostic Impact of Change in Nutritional Risk on Mortality and Heart Failure After Transcatheter Aortic Valve Replacement
Circulation. Cardiovascular interventions, Vol. 14, Núm. 2, pp. e009342
2020
-
Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention
European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770
-
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects
European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42
-
The impact of optimal medical therapy on patients with recurrent acute myocardial infarction: Subanalysis from the BleeMACS study
International Journal of Cardiology, Vol. 318, pp. 1-6
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Impact of Coronary Revascularization in Patients Who Underwent Transcatheter Aortic Valve Implantation
American Journal of Cardiology, Vol. 123, Núm. 6, pp. 948-955